DOCSLIB.ORG

Supplemental Table 6 RNA-Seq Simvastatin DEG FDR<0.05 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplemental Table 6 RNA-Seq Simvastatin DEG FDR<0.05 2 Supplemental Table 6 RNA-seq Simvastatin DEG FDR<0.05 2 Supplemental Table 7 RNA-seq Rosuvastatin DEG FDR<0.05 54 Supplemental Table 8 HMGCR LDLR PCSK9 Transcript variants 57 Supplemental Table 9 Proteome Simvastatin 58 Supplemental Table 10 Proteome Rosuvastatin 73 Supplemental Table S6. Differentially expressed genes at RNA-level from simvastatin-treated primary human myotubes (FDR<0.05) Controls Simvastatin normalized mean normalized mean Gene name counts counts foldChange pval padj Protein name SEPT4 1501.069803 801.4972929 0.533950714 0.00116405 0.025355381 Septin-4 SEPT8 1441.801849 869.1346625 0.60281145 0.001020561 0.022970752 Septin-8 SEPT11 15446.9098 7040.109901 0.455761702 1.61E-05 0.000918517 Septin-11 7SK_5 15.37250235 2.453813586 0.159623562 0.000193119 0.006512156 Lactosylceramide 4-alpha- A4GALT 337.0734749 647.7282426 1.921623299 3.99E-05 0.001884916 galactosyltransferase Alanine and arginine-rich AARD 16.34273774 2.936168593 0.179661978 0.000385314 0.011128664 domain-containing protein Alanyl-tRNA-editing protein AARSD1 677.076378 414.8116488 0.61265119 0.001650077 0.03285031 Aarsd1 Serine/threonine-protein AATK 107.0697753 36.78265486 0.343539106 6.61E-05 0.002811 kinase LMTK1 4-aminobutyrate aminotransferase, ABAT 275.9205401 151.5957045 0.549417975 0.000800454 0.019197327 mitochondrial ATP-binding cassette sub- ABCA8 499.8487363 269.8631157 0.539889563 0.000170156 0.005920437 family A member 8 ATP-binding cassette sub- family B member 10, ABCB10 299.3483499 481.8190029 1.609559575 0.002820587 0.049042586 mitochondrial Multidrug resistance ABCB4 21.30582529 54.3599761 2.551413773 0.001657132 0.032895175 protein 3 ATP-binding cassette sub- ABCB9 138.8827064 54.94028798 0.395587683 6.29E-05 0.002705609 family B member 9 Canalicular multispecific ABCC3 137.1951044 343.6263325 2.504654478 8.40E-07 8.14E-05 organic anion transporter 2 ATP-binding cassette sub- ABCD1 1969.667397 781.8006913 0.396920156 2.28E-07 2.71E-05 family D member 1 ATP-binding cassette sub- ABCE1 2086.066838 1184.803548 0.567960492 0.000182863 0.006245683 family E member 1 ATP-binding cassette sub- ABCF2 3515.65228 1991.402957 0.566439112 0.00014128 0.00514598 family F member 2 ATP-binding cassette sub- ABCG1 138.7478852 55.14821277 0.397470655 0.002052767 0.038212676 family G member 1 cDNA FLJ52972, weakly similar to Homo sapiens abhydrolase domain containing 3 (ABHD3), ABHD3 42.20842311 122.648491 2.905782352 0.000288392 0.008829437 mRNA ABI3 10.8281812 49.88598563 4.607051239 1.35E-05 0.000789097 ABI gene family member 3 cDNA FLJ54747, highly similar to Active breakpoint cluster region-related ABR 1871.163621 3757.169846 2.007932286 1.91E-06 0.000158586 protein Ankyrin repeat and BTB/POZ domain- ABTB1 519.6104715 881.5494112 1.69655821 0.000522543 0.014119048 containing protein 1 AC002066.1 40.10237568 8.568605257 0.213668271 3.95E-05 0.001871068 AC002117.1 90.87222631 239.7803571 2.63865393 0.001155924 0.025214773 AC002463.3 29.14019146 7.816251739 0.268229251 0.000664623 0.016712823 AC004041.2 122.0963524 227.1615798 1.860510779 0.000465097 0.012894214 AC004112.4 167.4996187 298.5961525 1.782667655 0.00066058 0.016638049 AC005013.1 45.71762421 16.34237587 0.357463367 0.002491365 0.044461503 AC005027.3 328.3891791 84.26356492 0.256596655 2.81E-13 1.68E-10 AC005592.2 101.4891551 50.66029425 0.499169534 0.001527709 0.031079739 AC006460.2 90.9547424 38.62806085 0.424695402 0.002486593 0.044445622 AC007228.11 280.2546707 459.0730292 1.638056658 0.001895232 0.035919228 AC007796.1 106.3847416 490.3962437 4.609648305 0.000581903 0.015266 AC009041.2 48.90001985 97.3395313 1.990582654 0.001914774 0.036163306 Simvastatin RNA-seq 1 Controls Simvastatin normalized mean normalized mean Gene name counts counts foldChange pval padj Protein name AC009133.20 116.0774353 490.4602582 4.225285105 1.13E-07 1.50E-05 AC009492.1 186.5152469 16.8019044 0.090083276 4.18E-06 0.000304706 AC010226.4 92.95251997 229.1465679 2.465200168 5.14E-07 5.42E-05 AC010970.2 1182.337019 17389.68498 14.70789184 1.15E-55 1.20E-51 AC011530.4 323.0503702 592.1147703 1.832886834 0.000135315 0.004957719 AC011747.7 19.38196496 53.30554582 2.750265308 0.000934512 0.0215805 AC016747.3 85.14028949 41.37769307 0.485994273 0.001134485 0.024886665 AC018647.3 840.9429372 222.1116231 0.26412211 0.000145896 0.005289343 AC018890.6 932.1042053 527.5690089 0.565997885 0.00030059 0.009077806 AC022596.6 1.570127796 16.46521327 10.4865434 0.000110439 0.00423591 AC025335.1 401.0579155 157.4717785 0.392640994 0.000274099 0.008475257 AC037459.4 184.3927076 97.63396508 0.529489297 0.00060751 0.015714443 AC073115.7 163.4556742 19.74747111 0.120812393 5.27E-12 2.22E-09 AC073283.4 255.649435 125.9739252 0.492760429 0.000522894 0.014119048 AC079922.3 27.86471568 79.13921936 2.840122981 0.000795911 0.019147424 AC093388.3 5525.579029 9657.408071 1.747763994 0.001791017 0.034326162 AC093673.5 190.6130609 103.2857499 0.541860822 0.000614285 0.015791705 AC096669.2 49.16574591 9.813631133 0.199603015 0.000509679 0.013870572 AC104532.2 77.36551653 177.1309296 2.289533341 1.21E-05 0.000716899 AC104695.3 24.22380896 62.70945326 2.588752799 0.000445332 0.012502266 AC104809.3 2.761599056 17.0356372 6.168758336 0.000733063 0.018083005 AC112229.4 12.52733469 1.427396597 0.113942561 0.000561114 0.014858114 AC112721.2 10.69546318 1.242447262 0.116165821 0.002192679 0.040358276 AC135048.13 96.78695739 300.3283372 3.102983556 5.76E-07 5.97E-05 AC144652.1 86.5688519 194.6452779 2.248444719 6.27E-05 0.002701219 AC144831.1 43.9560005 138.8545317 3.158943718 1.92E-07 2.37E-05 AC147651.3 32.32569508 118.0579551 3.652139722 0.000740096 0.018227584 Acetyl-CoA ACAT2 1064.936878 2495.672704 2.343493549 0.00032769 0.00974611 acetyltransferase, cytosolic Cytosolic acyl coenzyme A ACOT7 1099.701356 514.9548654 0.468267919 1.22E-06 0.000112115 thioester hydrolase Acyl-coenzyme A ACOT8 726.6825833 1476.644862 2.032035576 2.30E-06 0.000185534 thioesterase 8 Peroxisomal acyl-coenzyme ACOX3 800.8442561 382.449077 0.47755737 6.09E-06 0.000417313 A oxidase 3 Acetyl-coenzyme A ACSS2 664.1220082 1701.472947 2.561988499 5.15E-10 1.37E-07 synthetase, cytoplasmic Actin, aortic smooth ACTA2 22761.40606 4056.236354 0.178206757 5.88E-11 2.01E-08 muscle ACTB 40532.69565 18879.60271 0.465787 6.54E-05 0.002788137 Actin, cytoplasmic 1 Actin, gamma-enteric ACTG2 7.637200695 0.255427941 0.033445231 0.000797921 0.019180936 smooth muscle ACTN1 15057.17784 5539.320826 0.367885728 5.89E-08 8.77E-06 Alpha-actinin-1 ACVR2A 646.3692657 295.2762609 0.456822867 1.20E-06 0.000110603 Activin receptor type-2A Disintegrin and metalloproteinase domain- ADAM19 6253.971067 1277.082167 0.204203402 3.82E-09 8.49E-07 containing protein 19 A disintegrin and metalloproteinase with ADAMTS12 604.0498105 202.1974087 0.334736317 1.24E-06 0.000113657 thrombospondin motifs 12 A disintegrin and metalloproteinase with ADAMTS5 2076.507554 1172.948636 0.564866058 0.001733692 0.033660222 thrombospondin motifs 5 A disintegrin and metalloproteinase with ADAMTS6 200.9877148 102.8478976 0.511712358 0.000644598 0.016399421 thrombospondin motifs 6 ADAMTSL5 421.3024452 852.7596751 2.024103313 4.51E-05 0.00207994 ADAMTS-like protein 5 Chaperone activity of bc1 complex-like, ADCK3 1532.047944 2670.684743 1.74321225 0.002212938 0.040613531 mitochondrial ADCY9 2104.941801 4441.556678 2.110061511 1.75E-06 0.000149495 Adenylate cyclase type 9 Simvastatin RNA-seq 2 Controls Simvastatin normalized mean normalized mean Gene name counts counts foldChange pval padj Protein name ADD3 1452.359067 2551.071004 1.756501585 0.001693736 0.033260952 Gamma-adducin Hydroxyacid-oxoacid transhydrogenase, ADHFE1 81.3313592 186.4513799 2.292490642 6.77E-05 0.002866978 mitochondrial Adipogenesis regulatory ADIRF 244.5050701 449.4335625 1.838135963 0.000217057 0.007084757 factor ADORA1 2519.294154 965.9907407 0.383437059 1.11E-06 0.000104028 Adenosine receptor A1 Manganese-dependent ADP-ribose/CDP-alcohol ADPRM 288.3029375 158.2930789 0.549051218 0.001090348 0.024174178 diphosphatase ADRB2 160.1047743 72.52916085 0.453010606 0.000469453 0.012956242 Beta-2 adrenergic receptor Adenylosuccinate ADSSL1 142.3357557 303.2545061 2.130557459 0.000199961 0.006631129 synthetase isozyme 1 Androgen-dependent TFPI- ADTRP 176.3949384 37.04463945 0.210009651 2.03E-09 4.72E-07 regulating protein Actin filament-associated AFAP1L2 86.36572127 34.77695728 0.402670837 0.0004621 0.01283868 protein 1-like 2 AF4/FMR2 family member AFF3 51.19885195 15.50605457 0.302859419 7.06E-05 0.002969886 3 Arf-GAP with GTPase, ANK repeat and PH domain- AGAP2 493.7382513 173.1149163 0.350620832 9.97E-06 0.000616519 containing protein 2 Type-1 angiotensin II receptor-associated AGTRAP 433.5597821 749.8331341 1.729480374 0.000439822 0.012392294 protein AHCY 3760.858933 2297.490917 0.610895266 0.000916361 0.021314624 Adenosylhomocysteinase AHNAK2 6675.719832 11828.20409 1.771824521 0.000112877 0.004308154 Protein AHNAK2 Aryl hydrocarbon receptor AHRR 1889.345119 3870.141862 2.048403875 1.36E-05 0.000792085 repressor cDNA FLJ56675, highly similar to Activator of 90 kDa heat shock protein AHSA1 2862.898195 1760.533253 0.614947907 0.001251613 0.026831613 ATPase homolog 1 Allograft inflammatory AIF1L 6729.528856 3246.372626 0.482407119 0.000113408 0.00431784 factor 1-like AK7 9.941095502 26.9241959 2.708373126 0.00288021 0.049717978 Adenylate kinase 7 A-kinase anchor protein 1, AKAP1 2030.585746 3136.765895 1.544759142 0.002903636 0.049983675 mitochondrial Aldo-keto reductase family AKR1B10 57.41667791 222.2221745 3.870341903 2.44E-06 0.000193734 1 member
Load more

Recommended publications
  • Supplemental Information to Mammadova-Bach Et Al., “Laminin Α1 Orchestrates VEGFA Functions in the Ecosystem of Colorectal Carcinogenesis”
    Supplemental information to Mammadova-Bach et al., “Laminin α1 orchestrates VEGFA functions in the ecosystem of colorectal carcinogenesis” Supplemental material and methods Cloning of the villin-LMα1 vector The plasmid pBS-villin-promoter containing the 3.5 Kb of the murine villin promoter, the first non coding exon, 5.5 kb of the first intron and 15 nucleotides of the second villin exon, was generated by S. Robine (Institut Curie, Paris, France). The EcoRI site in the multi cloning site was destroyed by fill in ligation with T4 polymerase according to the manufacturer`s instructions (New England Biolabs, Ozyme, Saint Quentin en Yvelines, France). Site directed mutagenesis (GeneEditor in vitro Site-Directed Mutagenesis system, Promega, Charbonnières-les-Bains, France) was then used to introduce a BsiWI site before the start codon of the villin coding sequence using the 5’ phosphorylated primer: 5’CCTTCTCCTCTAGGCTCGCGTACGATGACGTCGGACTTGCGG3’. A double strand annealed oligonucleotide, 5’GGCCGGACGCGTGAATTCGTCGACGC3’ and 5’GGCCGCGTCGACGAATTCACGC GTCC3’ containing restriction site for MluI, EcoRI and SalI were inserted in the NotI site (present in the multi cloning site), generating the plasmid pBS-villin-promoter-MES. The SV40 polyA region of the pEGFP plasmid (Clontech, Ozyme, Saint Quentin Yvelines, France) was amplified by PCR using primers 5’GGCGCCTCTAGATCATAATCAGCCATA3’ and 5’GGCGCCCTTAAGATACATTGATGAGTT3’ before subcloning into the pGEMTeasy vector (Promega, Charbonnières-les-Bains, France). After EcoRI digestion, the SV40 polyA fragment was purified with the NucleoSpin Extract II kit (Machery-Nagel, Hoerdt, France) and then subcloned into the EcoRI site of the plasmid pBS-villin-promoter-MES. Site directed mutagenesis was used to introduce a BsiWI site (5’ phosphorylated AGCGCAGGGAGCGGCGGCCGTACGATGCGCGGCAGCGGCACG3’) before the initiation codon and a MluI site (5’ phosphorylated 1 CCCGGGCCTGAGCCCTAAACGCGTGCCAGCCTCTGCCCTTGG3’) after the stop codon in the full length cDNA coding for the mouse LMα1 in the pCIS vector (kindly provided by P.
    [Show full text]
  • Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB
    Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent
    [Show full text]
  • Expression Gene Network Analyses Reveal Molecular Mechanisms And
    www.nature.com/scientificreports OPEN Diferential expression and co- expression gene network analyses reveal molecular mechanisms and candidate biomarkers involved in breast muscle myopathies in chicken Eva Pampouille1,2, Christelle Hennequet-Antier1, Christophe Praud1, Amélie Juanchich1, Aurélien Brionne1, Estelle Godet1, Thierry Bordeau1, Fréderic Fagnoul2, Elisabeth Le Bihan-Duval1 & Cécile Berri1* The broiler industry is facing an increasing prevalence of breast myopathies, such as white striping (WS) and wooden breast (WB), and the precise aetiology of these occurrences remains poorly understood. To progress our understanding of the structural changes and molecular pathways involved in these myopathies, a transcriptomic analysis was performed using an 8 × 60 K Agilent chicken microarray and histological study. The study used pectoralis major muscles from three groups: slow-growing animals (n = 8), fast-growing animals visually free from defects (n = 8), or severely afected by both WS and WB (n = 8). In addition, a weighted correlation network analysis was performed to investigate the relationship between modules of co-expressed genes and histological traits. Functional analysis suggested that selection for fast growing and breast meat yield has progressively led to conditions favouring metabolic shifts towards alternative catabolic pathways to produce energy, leading to an adaptive response to oxidative stress and the frst signs of infammatory, regeneration and fbrosis processes. All these processes are intensifed in muscles afected by severe myopathies, in which new mechanisms related to cellular defences and remodelling seem also activated. Furthermore, our study opens new perspectives for myopathy diagnosis by highlighting fne histological phenotypes and genes whose expression was strongly correlated with defects. Te poultry industry relies on the production of fast-growing chickens, which are slaughtered at high weights and intended for cutting and processing.
    [Show full text]
  • Defining the Akt1 Interactome and Its Role in Regulating the Cell Cycle
    www.nature.com/scientificreports OPEN Defning the Akt1 interactome and its role in regulating the cell cycle Shweta Duggal1,3, Noor Jailkhani2, Mukul Kumar Midha2, Namita Agrawal3, Kanury V. S. Rao1 & Ajay Kumar1 Received: 13 July 2017 Cell growth and proliferation are two diverse processes yet always linked. Akt1, a serine/threonine Accepted: 8 January 2018 kinase, is a multi-functional protein implicated in regulation of cell growth, survival and proliferation. Published: xx xx xxxx Though it has a role in G1/S progression, the manner by which Akt1 controls cell cycle and blends cell growth with proliferation is not well explored. In this study, we characterize the Akt1 interactome as the cell cycle progresses from G0 to G1/S and G2 phase. For this, Akt1-overexpressing HEK293 cells were subjected to AP-MS. To distinguish between individual cell cycle stages, cells were cultured in the light, medium and heavy labelled SILAC media. We obtained 213 interacting partners of Akt1 from these studies. GO classifcation revealed that a signifcant number of proteins fall into functional classes related to cell growth or cell cycle processes. Of these, 32 proteins showed varying association with Akt1 in diferent cell cycle stages. Further analyses uncovered a subset of proteins showing counteracting efects so as to tune stage-specifc progression through the cycle. Thus, our study provides some novel perspectives on Akt1-mediated regulation of the cell cycle and ofers the framework for a detailed resolution of the downstream cellular mechanisms that are mediated by this kinase. Te mammalian cell cycle consists of an ordered series of events and is a highly coordinated and regulated pro- cess1.
    [Show full text]
  • Identification and Characterization of TPRKB Dependency in TP53 Deficient Cancers
    Identification and Characterization of TPRKB Dependency in TP53 Deficient Cancers. by Kelly Kennaley A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Molecular and Cellular Pathology) in the University of Michigan 2019 Doctoral Committee: Associate Professor Zaneta Nikolovska-Coleska, Co-Chair Adjunct Associate Professor Scott A. Tomlins, Co-Chair Associate Professor Eric R. Fearon Associate Professor Alexey I. Nesvizhskii Kelly R. Kennaley [email protected] ORCID iD: 0000-0003-2439-9020 © Kelly R. Kennaley 2019 Acknowledgements I have immeasurable gratitude for the unwavering support and guidance I received throughout my dissertation. First and foremost, I would like to thank my thesis advisor and mentor Dr. Scott Tomlins for entrusting me with a challenging, interesting, and impactful project. He taught me how to drive a project forward through set-backs, ask the important questions, and always consider the impact of my work. I’m truly appreciative for his commitment to ensuring that I would get the most from my graduate education. I am also grateful to the many members of the Tomlins lab that made it the supportive, collaborative, and educational environment that it was. I would like to give special thanks to those I’ve worked closely with on this project, particularly Dr. Moloy Goswami for his mentorship, Lei Lucy Wang, Dr. Sumin Han, and undergraduate students Bhavneet Singh, Travis Weiss, and Myles Barlow. I am also grateful for the support of my thesis committee, Dr. Eric Fearon, Dr. Alexey Nesvizhskii, and my co-mentor Dr. Zaneta Nikolovska-Coleska, who have offered guidance and critical evaluation since project inception.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS
    Protein identities in EVs isolated from U87-MG GBM cells as determined by NG LC-MS/MS. No. Accession Description Σ Coverage Σ# Proteins Σ# Unique Peptides Σ# Peptides Σ# PSMs # AAs MW [kDa] calc. pI 1 A8MS94 Putative golgin subfamily A member 2-like protein 5 OS=Homo sapiens PE=5 SV=2 - [GG2L5_HUMAN] 100 1 1 7 88 110 12,03704523 5,681152344 2 P60660 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 - [MYL6_HUMAN] 100 3 5 17 173 151 16,91913397 4,652832031 3 Q6ZYL4 General transcription factor IIH subunit 5 OS=Homo sapiens GN=GTF2H5 PE=1 SV=1 - [TF2H5_HUMAN] 98,59 1 1 4 13 71 8,048185945 4,652832031 4 P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] 97,6 5 5 35 917 375 41,70973209 5,478027344 5 P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 - [RINI_HUMAN] 96,75 1 12 37 173 461 49,94108966 4,817871094 6 P09382 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 - [LEG1_HUMAN] 96,3 1 7 14 283 135 14,70620005 5,503417969 7 P60174 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 - [TPIS_HUMAN] 95,1 3 16 25 375 286 30,77169764 5,922363281 8 P04406 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 - [G3P_HUMAN] 94,63 2 13 31 509 335 36,03039959 8,455566406 9 Q15185 Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 - [TEBP_HUMAN] 93,13 1 5 12 74 160 18,68541938 4,538574219 10 P09417 Dihydropteridine reductase OS=Homo sapiens GN=QDPR PE=1 SV=2 - [DHPR_HUMAN] 93,03 1 1 17 69 244 25,77302971 7,371582031 11 P01911 HLA class II histocompatibility antigen,
    [Show full text]
  • Multi-Modal Meta-Analysis of 1494 Hepatocellular Carcinoma Samples Reveals
    Author Manuscript Published OnlineFirst on September 21, 2018; DOI: 10.1158/1078-0432.CCR-18-0088 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Multi-modal meta-analysis of 1494 hepatocellular carcinoma samples reveals significant impact of consensus driver genes on phenotypes Kumardeep Chaudhary1, Olivier B Poirion1, Liangqun Lu1,2, Sijia Huang1,2, Travers Ching1,2, Lana X Garmire1,2,3* 1Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA 2Molecular Biosciences and Bioengineering Graduate Program, University of Hawaii at Manoa, Honolulu, HI 96822, USA 3Current affiliation: Department of Computational Medicine and Bioinformatics, Building 520, 1600 Huron Parkway, Ann Arbor, MI 48109 Short Title: Impact of consensus driver genes in hepatocellular carcinoma * To whom correspondence should be addressed. Lana X. Garmire, Department of Computational Medicine and Bioinformatics Medical School, University of Michigan Building 520, 1600 Huron Parkway Ann Arbor-48109, MI, USA, Phone: +1-(734) 615-5510 Current email address: [email protected] Grant Support: This research was supported by grants K01ES025434 awarded by NIEHS through funds provided by the trans-NIH Big Data to Knowledge (BD2K) initiative (http://datascience.nih.gov/bd2k), P20 COBRE GM103457 awarded by NIH/NIGMS, NICHD R01 HD084633 and NLM R01LM012373 and Hawaii Community Foundation Medical Research Grant 14ADVC-64566 to Lana X Garmire. 1 Downloaded from clincancerres.aacrjournals.org on October 1, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 21, 2018; DOI: 10.1158/1078-0432.CCR-18-0088 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • Profiling Data
    Compound Name DiscoveRx Gene Symbol Entrez Gene Percent Compound Symbol Control Concentration (nM) JNK-IN-8 AAK1 AAK1 69 1000 JNK-IN-8 ABL1(E255K)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317I)-nonphosphorylated ABL1 87 1000 JNK-IN-8 ABL1(F317I)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317L)-nonphosphorylated ABL1 65 1000 JNK-IN-8 ABL1(F317L)-phosphorylated ABL1 61 1000 JNK-IN-8 ABL1(H396P)-nonphosphorylated ABL1 42 1000 JNK-IN-8 ABL1(H396P)-phosphorylated ABL1 60 1000 JNK-IN-8 ABL1(M351T)-phosphorylated ABL1 81 1000 JNK-IN-8 ABL1(Q252H)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(Q252H)-phosphorylated ABL1 56 1000 JNK-IN-8 ABL1(T315I)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(T315I)-phosphorylated ABL1 92 1000 JNK-IN-8 ABL1(Y253F)-phosphorylated ABL1 71 1000 JNK-IN-8 ABL1-nonphosphorylated ABL1 97 1000 JNK-IN-8 ABL1-phosphorylated ABL1 100 1000 JNK-IN-8 ABL2 ABL2 97 1000 JNK-IN-8 ACVR1 ACVR1 100 1000 JNK-IN-8 ACVR1B ACVR1B 88 1000 JNK-IN-8 ACVR2A ACVR2A 100 1000 JNK-IN-8 ACVR2B ACVR2B 100 1000 JNK-IN-8 ACVRL1 ACVRL1 96 1000 JNK-IN-8 ADCK3 CABC1 100 1000 JNK-IN-8 ADCK4 ADCK4 93 1000 JNK-IN-8 AKT1 AKT1 100 1000 JNK-IN-8 AKT2 AKT2 100 1000 JNK-IN-8 AKT3 AKT3 100 1000 JNK-IN-8 ALK ALK 85 1000 JNK-IN-8 AMPK-alpha1 PRKAA1 100 1000 JNK-IN-8 AMPK-alpha2 PRKAA2 84 1000 JNK-IN-8 ANKK1 ANKK1 75 1000 JNK-IN-8 ARK5 NUAK1 100 1000 JNK-IN-8 ASK1 MAP3K5 100 1000 JNK-IN-8 ASK2 MAP3K6 93 1000 JNK-IN-8 AURKA AURKA 100 1000 JNK-IN-8 AURKA AURKA 84 1000 JNK-IN-8 AURKB AURKB 83 1000 JNK-IN-8 AURKB AURKB 96 1000 JNK-IN-8 AURKC AURKC 95 1000 JNK-IN-8
    [Show full text]
  • 1 Silencing Branched-Chain Ketoacid Dehydrogenase Or
    bioRxiv preprint doi: https://doi.org/10.1101/2020.02.21.960153; this version posted February 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Silencing branched-chain ketoacid dehydrogenase or treatment with branched-chain ketoacids ex vivo inhibits muscle insulin signaling Running title: BCKAs impair insulin signaling Dipsikha Biswas1, PhD, Khoi T. Dao1, BSc, Angella Mercer1, BSc, Andrew Cowie1 , BSc, Luke Duffley1, BSc, Yassine El Hiani2, PhD, Petra C. Kienesberger1, PhD, Thomas Pulinilkunnil1†, PhD 1Department of Biochemistry and Molecular Biology, Dalhousie Medicine New Brunswick, Saint John, New Brunswick, Canada, 2Department of Physiology and Biophysics, Dalhousie University, Halifax, Nova Scotia, Canada. †Correspondence to Thomas Pulinilkunnil, PhD Department of Biochemistry and Molecular Biology, Faculty of Medicine, Dalhousie University Dalhousie Medicine New Brunswick, 100 Tucker Park Road, Saint John E2L4L5, New Brunswick, Canada. Telephone: (506) 636-6973; Fax: (506) 636-6001; email: [email protected]. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.02.21.960153; this version posted February 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International
    [Show full text]
  • IL21R Expressing CD14+CD16+ Monocytes Expand in Multiple
    Plasma Cell Disorders SUPPLEMENTARY APPENDIX IL21R expressing CD14 +CD16 + monocytes expand in multiple myeloma patients leading to increased osteoclasts Marina Bolzoni, 1 Domenica Ronchetti, 2,3 Paola Storti, 1,4 Gaetano Donofrio, 5 Valentina Marchica, 1,4 Federica Costa, 1 Luca Agnelli, 2,3 Denise Toscani, 1 Rosanna Vescovini, 1 Katia Todoerti, 6 Sabrina Bonomini, 7 Gabriella Sammarelli, 1,7 Andrea Vecchi, 8 Daniela Guasco, 1 Fabrizio Accardi, 1,7 Benedetta Dalla Palma, 1,7 Barbara Gamberi, 9 Carlo Ferrari, 8 Antonino Neri, 2,3 Franco Aversa 1,4,7 and Nicola Giuliani 1,4,7 1Myeloma Unit, Dept. of Medicine and Surgery, University of Parma; 2Dept. of Oncology and Hemato-Oncology, University of Milan; 3Hematology Unit, “Fondazione IRCCS Ca’ Granda”, Ospedale Maggiore Policlinico, Milan; 4CoreLab, University Hospital of Parma; 5Dept. of Medical-Veterinary Science, University of Parma; 6Laboratory of Pre-clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture; 7Hematology and BMT Center, University Hospital of Parma; 8Infectious Disease Unit, University Hospital of Parma and 9“Dip. Oncologico e Tecnologie Avanzate”, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy ©2017 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2016.153841 Received: August 5, 2016. Accepted: December 23, 2016. Pre-published: January 5, 2017. Correspondence: [email protected] SUPPLEMENTAL METHODS Immunophenotype of BM CD14+ in patients with monoclonal gammopathies. Briefly, 100 μl of total BM aspirate was incubated in the dark with anti-human HLA-DR-PE (clone L243; BD), anti-human CD14-PerCP-Cy 5.5, anti-human CD16-PE-Cy7 (clone B73.1; BD) and anti-human CD45-APC-H 7 (clone 2D1; BD) for 20 min.
    [Show full text]
  • Anti-Inflammatory Role of Curcumin in LPS Treated A549 Cells at Global Proteome Level and on Mycobacterial Infection
    Anti-inflammatory Role of Curcumin in LPS Treated A549 cells at Global Proteome level and on Mycobacterial infection. Suchita Singh1,+, Rakesh Arya2,3,+, Rhishikesh R Bargaje1, Mrinal Kumar Das2,4, Subia Akram2, Hossain Md. Faruquee2,5, Rajendra Kumar Behera3, Ranjan Kumar Nanda2,*, Anurag Agrawal1 1Center of Excellence for Translational Research in Asthma and Lung Disease, CSIR- Institute of Genomics and Integrative Biology, New Delhi, 110025, India. 2Translational Health Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, 110067, India. 3School of Life Sciences, Sambalpur University, Jyoti Vihar, Sambalpur, Orissa, 768019, India. 4Department of Respiratory Sciences, #211, Maurice Shock Building, University of Leicester, LE1 9HN 5Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia- 7003, Bangladesh. +Contributed equally for this work. S-1 70 G1 S 60 G2/M 50 40 30 % of cells 20 10 0 CURI LPSI LPSCUR Figure S1: Effect of curcumin and/or LPS treatment on A549 cell viability A549 cells were treated with curcumin (10 µM) and/or LPS or 1 µg/ml for the indicated times and after fixation were stained with propidium iodide and Annexin V-FITC. The DNA contents were determined by flow cytometry to calculate percentage of cells present in each phase of the cell cycle (G1, S and G2/M) using Flowing analysis software. S-2 Figure S2: Total proteins identified in all the three experiments and their distribution betwee curcumin and/or LPS treated conditions. The proteins showing differential expressions (log2 fold change≥2) in these experiments were presented in the venn diagram and certain number of proteins are common in all three experiments.
    [Show full text]